MCID: ATN004
MIFTS: 43

Autonomic Neuropathy

Categories: Neuronal diseases

Aliases & Classifications for Autonomic Neuropathy

MalaCards integrated aliases for Autonomic Neuropathy:

Name: Autonomic Neuropathy 12 55 15 72

Classifications:



External Ids:

Disease Ontology 12 DOID:11504
NCIt 50 C27033
UMLS 72 C0259749

Summaries for Autonomic Neuropathy

MalaCards based summary : Autonomic Neuropathy is related to hereditary sensory and autonomic neuropathy type 1 and neuropathy, hereditary sensory and autonomic, type v. An important gene associated with Autonomic Neuropathy is RETREG1 (Reticulophagy Regulator 1), and among its related pathways/superpathways is Activation of TRKA receptors. The drugs Quinapril and Vildagliptin have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and kidney, and related phenotypes are behavior/neurological and mortality/aging

Wikipedia : 75 Autonomic neuropathy (AN or AAN) is a form of polyneuropathy that affects the non-voluntary, non-sensory... more...

Related Diseases for Autonomic Neuropathy

Diseases related to Autonomic Neuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 443)
# Related Disease Score Top Affiliating Genes
1 hereditary sensory and autonomic neuropathy type 1 34.7 SPTLC2 SPTLC1
2 neuropathy, hereditary sensory and autonomic, type v 34.2 NTRK1 NGF
3 neuropathy, hereditary sensory and autonomic, type iii 34.1 NGF ELP1
4 neuropathy, hereditary sensory and autonomic, type ic 34.1 SPTLC2 SPTLC1
5 neuropathy, hereditary sensory and autonomic, type iia 33.5 WNK1 SCN9A RETREG1 KIF1A ELP1
6 neuropathy, hereditary sensory, type ie 33.4 SPTLC2 SPTLC1
7 dysautonomia 33.0 NTRK1 ELP1
8 sensory peripheral neuropathy 32.6 SPTLC1 NTRK1 NGF
9 diabetic autonomic neuropathy 32.3 NGF INS EPO AKR1B1
10 hereditary sensory neuropathy 31.8 WNK1 SPTLC2 SPTLC1 RETREG1 NTRK1 NGF
11 autonomic nervous system disease 31.1 NGF INS ALB
12 anhidrosis 30.8 NTRK1 NGF
13 acroosteolysis 30.4 RETREG1 ALB
14 diabetic polyneuropathy 30.4 NGF AKR1B1
15 microvascular complications of diabetes 3 30.2 INS ALB
16 neurogenic arthropathy 30.2 SPTLC1 NGF
17 diabetic neuropathy 30.0 SCN9A NTRK1 NGF INS EPO AKR1B1
18 neuropathy 29.7 WNK1 SPTLC2 SPTLC1 SCN9A RETREG1 NGF
19 diabetes mellitus, insulin-dependent 29.6 INS ALB AKR1B1
20 microvascular complications of diabetes 5 29.5 INS ALB AKR1B1
21 background diabetic retinopathy 29.5 INS ALB
22 hyperglycemia 29.4 INS ALB AKR1B1
23 uremia 29.3 INS EPO ALB
24 prediabetes syndrome 28.8 INS ALB
25 kidney disease 28.6 INS EPO ALB AKR1B1
26 peripheral nervous system disease 28.2 SPTLC1 SCN9A NGF INS ELP1 ALB
27 idiopathic peripheral autonomic neuropathy 12.5
28 insensitivity to pain, congenital, with anhidrosis 12.4
29 neuropathy, hereditary sensory and autonomic, type vii 12.4
30 neuropathy, hereditary sensory and autonomic, type iib 12.3
31 neuropathy, hereditary sensory and autonomic, type vi 12.3
32 neuropathy, hereditary sensory and autonomic, type ia 12.3
33 x-linked hereditary sensory and autonomic neuropathy with deafness 12.3
34 hereditary sensory and autonomic neuropathy with deafness and global delay 12.3
35 autosomal dominant hereditary sensory and autonomic neuropathy 12.3
36 autosomal recessive hereditary sensory and autonomic neuropathy 12.3
37 spastic paraplegia 49, autosomal recessive 12.2
38 neuropathy, hereditary sensory and autonomic, type viii 12.2
39 neuropathy, hereditary sensory and autonomic, type i, with cough and gastroesophageal reflux 12.0
40 sptlc1-related hereditary sensory neuropathy 11.7
41 autonomic dysfunction 11.6
42 autoimmune autonomic ganglionopathy 11.6
43 hereditary neuropathies 11.5
44 indifference to pain, congenital, autosomal recessive 11.5
45 hereditary amyloidosis 11.5
46 neuropathy, hereditary sensory, type iic 11.5
47 lipomatosis, multiple symmetric 11.5
48 spastic paraplegia type 49 11.5
49 deafness, x-linked 5 11.3
50 prp systemic amyloidosis 11.3

Graphical network of the top 20 diseases related to Autonomic Neuropathy:



Diseases related to Autonomic Neuropathy

Symptoms & Phenotypes for Autonomic Neuropathy

MGI Mouse Phenotypes related to Autonomic Neuropathy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.06 AKR1B1 ELP1 INS KIF1A NGF NTRK1
2 mortality/aging MP:0010768 10.03 AKR1B1 ALB ELP1 EPO INS KIF1A
3 growth/size/body region MP:0005378 10.02 AKR1B1 ELP1 INS KIF1A NGF NTRK1
4 integument MP:0010771 9.97 ELP1 EPO INS KIF1A NGF NTRK1
5 muscle MP:0005369 9.7 ALB ELP1 EPO INS NGF NTRK1
6 nervous system MP:0003631 9.61 ELP1 INS KIF1A NGF NTRK1 RETREG1
7 renal/urinary system MP:0005367 9.1 AKR1B1 ALB ELP1 INS SCN9A WNK1

Drugs & Therapeutics for Autonomic Neuropathy

Drugs for Autonomic Neuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 178)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
2
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
3
Testosterone enanthate Approved Phase 4 315-37-7 9416
4
Methyltestosterone Approved Phase 4 58-18-4 6010
5
Testosterone Approved, Experimental, Investigational Phase 4 481-30-1, 58-22-0 6013 10204
6
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
7
Lenograstim Approved, Investigational Phase 4 135968-09-1
8
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
9
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
10
Glimepiride Approved Phase 4 93479-97-1 3476
11
Metformin Approved Phase 4 657-24-9 4091 14219
12
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
13
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
14
Norepinephrine Approved Phase 4 51-41-2 439260
15
Donepezil Approved Phase 4 120014-06-4 3152
16
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
17
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
18 Benphothiamine Phase 4
19 Vasodilator Agents Phase 4
20 Alpha-lipoic Acid Phase 4
21 Thioctic Acid Phase 4
22 Neurotransmitter Agents Phase 4
23 Dipeptidyl-Peptidase IV Inhibitors Phase 4
24 Calcium, Dietary Phase 4
25 Androgens Phase 4
26 Anabolic Agents Phase 4
27 Antineoplastic Agents, Hormonal Phase 4
28 Testosterone 17 beta-cypionate Phase 4
29 Adjuvants, Immunologic Phase 4
30 Rosuvastatin Calcium Phase 4 147098-20-2
31 Dopamine agonists Phase 4
32 Phosphodiesterase Inhibitors Phase 4
33 Phosphodiesterase 5 Inhibitors Phase 4
34 insulin Phase 4
35 Insulin, Globin Zinc Phase 4
36 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,... Phase 4
37 Immunologic Factors Phase 4
38 Immunosuppressive Agents Phase 4
39 Anti-Arrhythmia Agents Phase 4
40 Liver Extracts Phase 4
41
protease inhibitors Phase 4
42 HIV Protease Inhibitors Phase 4
43 Angiotensin-Converting Enzyme Inhibitors Phase 4
44 Antihypertensive Agents Phase 4
45 Sodium-Glucose Transporter 2 Inhibitors Phase 4
46 Sodium Chloride Symporter Inhibitors Phase 4
47 diuretics Phase 4
48 Natriuretic Agents Phase 4
49 5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-dioxabicyclo(3.2.1)... Phase 4
50 Angiotensin Receptor Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 127)
# Name Status NCT ID Phase Drugs
1 Inspiratory Muscle Training in Patients With Autonomic Neuropathic: a Randomized Trial Unknown status NCT00752440 Phase 4
2 Effects of a Chronical Treatment With Benfotiamine in People With Type 2 Diabetes Mellitus on Pre- and Postprandial Endothelial Function, as Well as on the Function of the Autonomic Nervous System Unknown status NCT00446810 Phase 4 Benfotiamine;Placebo
3 Efficacy of Administration of Angiotensin Converting Enzyme Inhibition on Autonomic and Peripheral Neuropathy in Patients With Diabetes Mellitus Completed NCT03031834 Phase 4 Quinapril
4 The Effect of α-lipoic Acid Treatment in Patient With Cardiac Autonomic Neuropathy by Comparing the Change of HRV Index & ANS Function:A 6month Multicenter, Randomized, Open Label Clinical Trial CANON Study Completed NCT02056366 Phase 4 α-lipoic acid
5 Effects of DPP4 Inhibitor Versus SGLT2 Inhibitor on Ischemic Burden in Stable Ischemic Heart Disease Patients Completed NCT03178591 Phase 4 vildagliptin;Dapagliflozin
6 Bone Marrow Responsiveness to Pharmacologic Mobilization of Progenitor Cells in Diabetic Versus Non-diabetic Patients Completed NCT01102699 Phase 4 Filgrastim, hrG-CSF
7 Statin Therapy is Associated With Low Testosterone and Sexual Function in Men With Type 2 Diabetes Completed NCT02612714 Phase 4 Rosuvastatin
8 Impact of Timed Bromocriptine-QR Therapy Upon Measures of Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects Completed NCT02682901 Phase 4 Cycloset;Placebo
9 Phase IV Study on New Insights in Remodeling of Diabetic Cardiomyopathy: Gender Difference in Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A Completed NCT01803828 Phase 4 Tadalafil;Placebo
10 RESTORE: A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy Recruiting NCT02586623 Phase 4 Droxidopa capsules;Placebo capsules
11 Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D) Active, not recruiting NCT02973477 Phase 4 Dapagliflozin;Glimepiride
12 A Double-blind, Randomized, Parallel 2- Arm Study to Compare the Efficacy of Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes Who Are Receiving Background Standard-of-care Cardio-metabolic Therapy With Metformin, an Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker, and a Statin. Not yet recruiting NCT03640221 Phase 4 Ertugliflozin;Hydrochlorothiazide 12.5mg
13 Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy Terminated NCT00619983 Phase 4 donepezil;duloxetine;donepezil 2.5 mg and duloxetine 30mg;placebo;gabapentin
14 Effect of Pioglitazone on Intima Media Thickness, Endothelial Function, and Heart Rate Variability in Patients With Impaired Glucose Tolerance Withdrawn NCT00306826 Phase 4 pioglitazone;simvastatin;pioglitazone + simvastatin
15 A 16-week, Randomised, Double-blind, Placebo-controlled, Single-centre Study to Investigate Fluid Retention in Insulin-treated Subjects With Type 2 Diabetes Mellitus and Varying Degrees of Autonomic Neuropathy When Administered Rosiglitazone 4mg Twice Daily Completed NCT00422955 Phase 3 rosiglitazone
16 Oxidative Stress and Cardiovascular Denervation in Diabetes: An Interventional Trial Completed NCT00116207 Phase 3 ORAL ANTIOXIDANT
17 Anti-Nephropathic Effects of Chronic Intermittent Intravenous Insulin Therapy (CIIIT) Completed NCT00594152 Phase 3 CIIIT
18 A Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy. Completed NCT01522235 Phase 2, Phase 3 Double blinded IVIg
19 The Effect of Diflunisal on Familial Amyloidosis Completed NCT00294671 Phase 2, Phase 3 diflunisal
20 Carbidopa for the Treatment of Nausea and Vomiting in Familial Dysautonomia Completed NCT01212484 Phase 3 Carbidopa;Placebo
21 A Multi-center, Open-label Study to Assess the Long-term Safety of Droxidopa in Subjects With Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic Neurogenic Orthostatic Hypotension Completed NCT01132326 Phase 3 Droxidopa
22 Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Neuroprotective Effect of Vitamin B6 and Vitamin B12 Against Vincristine Induced Neurotoxicity in Acute Lymphoblastic Leukaemia Patients Recruiting NCT03593304 Phase 2, Phase 3 Injection Mecobalamin;Tablet Pyridoxine hydrochlorid;Normal saline;Oral Placebo
23 Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy-TINSAL -T1DN Recruiting NCT02936843 Phase 2, Phase 3 Salsalate;PLACEBO
24 A Phase II, Open-label, Dose Escalation and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis Unknown status NCT01730716 Phase 2
25 Effect of a DPP-IV Inhibitor Treatment on the Secretion of Glucagon in Patients Presenting With Type 1 Diabetes Mellitus With or Without Autonomic Neuropathy Completed NCT01452113 Phase 2 Vildagliptin
26 A Multicenter, Randomized, Double-Blind, Placebo and Active Controlled Study Comparing the Analgesic Efficacy and Safety of ABT-639 to Placebo in Subjects With Diabetic Neuropathic Pain Completed NCT01345045 Phase 2 ABT-639;pregabalin;Placebo
27 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of L-Serine in Subjects With Hereditary Sensory Neuropathy Type 1 Completed NCT01733407 Phase 1, Phase 2 L-serine;placebo
28 Chronic Diabetic Painful Neuropathy and Cardiovascular Risk Factors in NIDDM: An Alternative Approach. Completed NCT00010751 Phase 2
29 A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Study to Evaluate the Efficacy and Safety of 3 Doses of TAK-583 in Subjects With Mild to Moderate Diabetic Peripheral Neuropathy Completed NCT00760955 Phase 2 TAK-583;TAK-583;TAK-583;Placebo
30 Improving Diabetic Foot Ulcers With Atorvastatin Completed NCT00134550 Phase 2 Atorvastatin (10 mg or 80 mg)
31 Carbidopa in Familial Dysautonomia: Phase-II Study, Investigational New Drug (IND) 117435, Date: 01/07/13 Recruiting NCT02553265 Phase 2 Carbidopa Low Dose;Carbidopa High Dose
32 A Double-Blind, Randomized, Placebo-Controlled Trial To Evaluate The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes Recruiting NCT02915263 Phase 2 IGIV-C;0.9% Sodium Chloride
33 Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes Recruiting NCT03085771 Phase 2 desferal;Isotonic saline
34 Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism Not yet recruiting NCT03446807 Phase 2 Droxidopa;Placebo Oral Tablet
35 The Safety , Tolerability and Efficacy of Dronabinol, a Synthetic Endocannabinoid Receptor Agonist, for the Treatment of Nausea and Vomiting in Patients With Familial Dysautonomia Withdrawn NCT02608931 Phase 2 Dronabinol
36 Cardiac Autonomic Neuropathy in Patients With Metabolic Syndrome Completed NCT00907127 Phase 1
37 The Safety and Tolerability of Kinetin, a Nutritional Supplement That Corrects the Splicing Defect, in Patients With Familial Dysautonomia Completed NCT02274051 Phase 1
38 A Dose Response Trial of Droxidopa to Treat Hypotension in Persons With SCI Completed NCT01354158 Phase 1 Droxidopa
39 Phase I Dose Escalation Study of N-acetylcysteine (NAC) Administered Intravenously (IV) in Conjunction With Intraperitoneal (IP) Administered Cisplatin and IV/IP Paclitaxel in Patients With Stage III or IV Ovarian Cancer Withdrawn NCT01138137 Phase 1 Paclitaxel;N-acetylcysteine;Cisplatin
40 A Comparison Between Pupillometry, Heart Rate Variability and Metaiodobenzylguanidine Scintigraphy for the Diagnosis of Early Diabetic Autonomic Neuropathy in Type 1 Diabetes Unknown status NCT01822431
41 The Relationship Between Vascular Adhesion Protein-1 and Diabetic Cardiovascular Autonomic Neuropathy Unknown status NCT01706289
42 Sleep Apnea in Type 1 Diabetes : Prevalence, Role of Glycemic Control and Autonomic Neuropathy Unknown status NCT01935765 Early Phase 1
43 Silent Myocardial Ischemia in Patients With Diabetes Type 2: Diagnostic Value of Myocardial Strains Left Ventricular Resting Echocardiography 2D and 3D, Compared to Stress Echocardiography Unknown status NCT02885428
44 Effect of DPP-IV Inhibitor on Glycemic Control and Autonomic Neuropathy in Adult Patients With Diabetes Mellitus Unknown status NCT01545024 Sitagliptin, 50 mg once per day per os
45 ECG Changes in Children and Adolescents With Type 1 Diabetes Unknown status NCT03260998
46 Autonomic Cardiovascular Neuropathy in Recently Diagnosed DM2 Patients and in Pre-Diabetes Patients Unknown status NCT02931773
47 Safety and Efficacy of Single Ankle, Single Popliteal or Combined Ankle and Popliteal Block for Diabetic Foot Surgery: A Comparative Study Unknown status NCT03155568 Bupivacaine
48 Gastrointestinal Motility Among Diabetes Patients Unknown status NCT02573519 3D-Transit during treatment with Pyridostigmine
49 Acute Effects of Low-level Laser Therapy in Functional Capacity of Patients With Chronic Kidney Disease: Randomized Clinical Trial Unknown status NCT02944760
50 Effects of High-intensity Inspiratory Muscle Training in Chronic Kidney Disease: Randomized Clinical Trial Unknown status NCT03082404

Search NIH Clinical Center for Autonomic Neuropathy

Genetic Tests for Autonomic Neuropathy

Anatomical Context for Autonomic Neuropathy

MalaCards organs/tissues related to Autonomic Neuropathy:

41
Heart, Testes, Kidney, Liver, Skin, Brain, Spinal Cord

Publications for Autonomic Neuropathy

Articles related to Autonomic Neuropathy:

(show top 50) (show all 4241)
# Title Authors PMID Year
1
Perspectives of nuclear diagnostic imaging in diabetic cardiomyopathy. 9 38
19939648 2010
2
Erythropoietin response to anemia and its association with autonomic neuropathy in type 2 diabetic patients without advanced renal failure. 9 38
19303331 2010
3
In vitro receptor binding properties of a "painless" NGF mutein, linked to hereditary sensory autonomic neuropathy type V. 9 38
19945432 2010
4
Small bowel bacterial overgrowth and type 1 diabetes. 9 38
20085122 2009
5
Complement C1Q polymorphisms modulate onset in familial amyloidotic polyneuropathy TTR Val30Met. 9 38
19493541 2009
6
Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). 9 38
19470886 2009
7
A novel NGFB point mutation: a phenotype study of heterozygous patients. 9 38
18420729 2009
8
Loss of mouse Ikbkap, a subunit of elongator, leads to transcriptional deficits and embryonic lethality that can be rescued by human IKBKAP. 9 38
19015235 2009
9
Gastroparesis is associated with oxytocin deficiency, oesophageal dysmotility with hyperCCKemia, and autonomic neuropathy with hypergastrinemia. 9 38
19243587 2009
10
Enhanced transthyretin tetramer stability following expression of an amyloid disease transsuppressor variant in mammalian cells. 9 38
19065606 2009
11
Specific pathogen free conditions prevent transthyretin amyloidosis in mouse models. 9 38
18357510 2008
12
Plantar fascia thickness, a measure of tissue glycation, predicts the development of complications in adolescents with type 1 diabetes. 9 38
18332152 2008
13
The pathophysiology and diagnosis of orthostatic hypotension. 9 38
18368300 2008
14
Potential roles of erythropoietin in the management of anaemia and other complications diabetes. 9 38
17645562 2008
15
Aldose reductase, still a compelling target for diabetic neuropathy. 9 38
18220710 2008
16
A humanized IKBKAP transgenic mouse models a tissue-specific human splicing defect. 9 38
17644305 2007
17
In vivo stabilization of mutant human transthyretin in transgenic mice. 9 38
17701470 2007
18
Lower heart rate variability is associated with higher plasma concentrations of IL-6 in type 1 diabetes. 9 38
17609399 2007
19
[The diagnosis and management of familial amyloid polyneuropathy]. 9 38
17086153 2006
20
Management strategies for brittle diabetes. 9 38
17072232 2006
21
Impact of liver transplantation on cardiac autonomic denervation in familial amyloid polyneuropathy. 9 38
16862048 2006
22
Performing only one cardiovascular reflex test has a high positive predictive value for diagnosing autonomic neuropathy in patients with chronic renal failure on hemodialysis. 9 38
16825086 2006
23
Nerve growth factor-tyrosine kinase A pathway is involved in thermoregulation and adaptation to stress: studies on patients with hereditary sensory and autonomic neuropathy type IV. 9 38
15695606 2005
24
Familial insensitivity to pain (HSAN V) and a mutation in the NGFB gene. A neurophysiological and pathological study. 9 38
15468048 2004
25
Heart failure in diabetes mellitus: causal and treatment considerations. 9 38
15729210 2004
26
Kidney and anemia in familial amyloidosis type I. 9 38
15496172 2004
27
A case of insulin edema with inappropriate hyperaldosteronism. 9 38
15762045 2004
28
Does autonomic neuropathy play a role in erythropoietin regulation in non-proteinuric Type 2 diabetic patients? 9 38
15498082 2004
29
The evaluation of autonomic nervous function in a patient with hereditary sensory and autonomic neuropathy type IV with novel mutations of the TRKA gene. 9 38
15534759 2004
30
Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. 9 38
15294881 2004
31
The anaesthetic management of patients with congenital insensitivity to pain with anhidrosis. 9 38
15078381 2004
32
Anaemia in diabetes. 9 38
15103543 2004
33
Severe and disabling diabetic autonomic neuropathy: a case report. 9 38
15120708 2004
34
Risk factors for coronary heart disease in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study. 9 38
14747240 2004
35
Erythropoietin treatment in the neuropsychiatric porphyrias. 9 38
14637267 2003
36
Nerve growth factor and diabetic neuropathy. 9 38
14668049 2003
37
Gallbladder motility in obesity, diabetes mellitus and coeliac disease. 9 38
12974503 2003
38
Insulin resistant state in type 2 diabetes is related to advanced autonomic neuropathy. 9 38
12716078 2003
39
Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. 9 38
12706936 2003
40
Tissue-specific reduction in splicing efficiency of IKBKAP due to the major mutation associated with familial dysautonomia. 9 38
12577200 2003
41
[Erythropoietin administration in diabetic patients]. 9 38
14974347 2003
42
Diabetes mellitus and heart failure. 9 38
15815121 2003
43
A new transthyretin variant Leu55Gln in a patient with systemic amyloidosis. 9 38
12557757 2002
44
No mutation in the TRKA (NTRK1) gene encoding a receptor tyrosine kinase for nerve growth factor in a patient with hereditary sensory and autonomic neuropathy type V. 9 38
12210794 2002
45
Autonomic neuropathy is associated with impaired pancreatic polypeptide and neuropeptide Y responses to insulin-induced hypoglycaemia in Type I diabetic patients. 9 38
12187924 2002
46
Observations on haematological and cardiovascular effects of erythropoietin treatment in multiple system atrophy with sympathetic failure. 9 38
12269555 2002
47
Prevalence of Q-T interval dispersion in type 1 diabetes and its relation with cardiac ischemia : the EURODIAB IDDM Complications Study Group. 9 38
11919128 2002
48
Neuroadrenergic denervation of the lung in type I diabetes mellitus complicated by autonomic neuropathy. 9 38
11834655 2002
49
Changes of gastric emptying rate and gastrin levels are early indicators of autonomic neuropathy in type II diabetic patients. 9 38
11710799 2001
50
Erythropoietin treatment of postural hypotension in anemic type 1 diabetic patients with autonomic neuropathy: a case study of four patients. 9 38
11375382 2001

Variations for Autonomic Neuropathy

Expression for Autonomic Neuropathy

Search GEO for disease gene expression data for Autonomic Neuropathy.

Pathways for Autonomic Neuropathy

Pathways related to Autonomic Neuropathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
9.66 NTRK1 NGF

GO Terms for Autonomic Neuropathy

Cellular components related to Autonomic Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 9.02 SCN9A NTRK1 NGF KIF1A DST
2 serine C-palmitoyltransferase complex GO:0017059 8.96 SPTLC2 SPTLC1

Biological processes related to Autonomic Neuropathy according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.77 NTRK1 NGF EPO ALB AKR1B1
2 negative regulation of neuron apoptotic process GO:0043524 9.65 RETREG1 NTRK1 NGF
3 response to axon injury GO:0048678 9.52 NTRK1 EPO
4 response to electrical stimulus GO:0051602 9.51 NTRK1 EPO
5 ceramide biosynthetic process GO:0046513 9.49 SPTLC2 SPTLC1
6 neurotrophin TRK receptor signaling pathway GO:0048011 9.46 NTRK1 NGF
7 nerve growth factor signaling pathway GO:0038180 9.43 NTRK1 NGF
8 sensory perception of pain GO:0019233 9.43 SCN9A RETREG1 NTRK1
9 sphingosine biosynthetic process GO:0046512 9.4 SPTLC2 SPTLC1
10 sphingomyelin biosynthetic process GO:0006686 9.32 SPTLC2 SPTLC1
11 positive regulation of lipophagy GO:1904504 9.16 SPTLC2 SPTLC1
12 sphinganine biosynthetic process GO:0046511 8.96 SPTLC2 SPTLC1
13 positive regulation of Ras protein signal transduction GO:0046579 8.8 NTRK1 NGF EPO

Molecular functions related to Autonomic Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase activator activity GO:0030295 9.16 WNK1 EPO
2 pyridoxal phosphate binding GO:0030170 9.13 SPTLC2 SPTLC1 ALB
3 serine C-palmitoyltransferase activity GO:0004758 8.62 SPTLC2 SPTLC1

Sources for Autonomic Neuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....